OBJECTIVES: Remission by Boolean-based definition(all scores on the TJC and SJC,CRP(mg/dl), and PGA≤1) and by SDAI(<3.3) were proposed by ACR/EULAR.Using patient reported outcomes as anchors, this analysis validated these remission criteria against traditional DAS28(using CRP<2.6)remission. METHODS: Efficacy of golimumab(GLM) was assessed in MTX-naïve RA patients(GO-BEFORE,N=637),RA patients with inadequate response to MTX(GO-FORWARD,N=444) and RA patients previously treated with biologic anti-TNFα agent(s) with baseline MTX use(GO-AFTER,N=305).Pooled data from patients who received placebo(PBO)+MTX, or GLM(50or100mg)+MTX,q4wks were used for this analysis.Patient reported outcomes were measured using:HAQ, SF-36 PCS and MCS, FACIT-Fatigue, and VAS 0-10 of impact of RA on daily work productivity.Descriptive statistics were provided for patient reported outcomes among patients in remission as defined remission definitions. RESULTS: Greater proportions of patients treated with GLM+MTX vs patients treated with PBO+MTX achieved remission by each remission definition.In the pooled analysis,the remission rate at wk24 was the highest(20.2%)by DAS28 vs remission by SDAI(10.6%,p<0.001) and remission by Boolean-based definition(8.6%p<0.001).Patients with remission by DAS28 achieved normal physical function(HAQ≤0.5),normal SF-36PCS and MCS(≥50) by 67.8%,38.4%,62.2%,respectively;these parameters were numerically lower vs. patients with remission by SDAI(81.3%,62.8%,72.1%,respectively) or by Boolean-based definition(82.0%,63.5%,74.3%, respectively). Patients in remission by DAS28 had higher HAQ scores(0.43±0.49)vs patients in remission by SDAI(0.26±0.41) or Boolean-based criteria(0.28±0.44).Similar results were observed in measures of   FACIT-Fatigue and productivity VAS scores.Among MTX-naive patients in GO-BEFORE who achieved remission by DAS28,71.3% achieved normal physical function vs 86.9% of those in remission by SDAI and 86.5% of patients in remission by Boolean-based definition.Among anti-TNFα experienced patients in GO-AFTER,62.1% of those in remission by DAS28 achieved normal physical function vs. 65.0% of those in remission by SDAI, and 66.7% of patients in remission by Boolean-based definition. CONCLUSIONS: While disease remission has been adapted as a target in the management of RA, more stringent remission criteria proposed by ACR/EULAR can provide optimal patient-reported outcomes.